CYP2C9 gene and susceptibility to major depressive disorder

Pharmacogenomics Journal

Volumn 3, Issue 5, 2003, Pages 300-302

  Llerena, A ^a,b   Berecz, R ^a,c   Dorado, P ^a   Gonzalez A P ^a   Penas Lledo E M ^a,b   De la Rubia, A ^d  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d Hospital de Merida   (Spain)

Author keywords

CYP2C9 gene; Depression; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C9; FLUOXETINE; HALOPERIDOL; MIANSERIN; MONOAMINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLISM; MONOAMINERGIC SYSTEM; MOOD DISORDER; NEUROMODULATION; NEUROTRANSMISSION; OUTPATIENT; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED;

EID: 0242575123     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500197     Document Type: Article

References (16)

1. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-470.
2. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acto Psychiatr Scand 1993; 87: 23-28.
3. Martínez C, Agúndez JA, Gervasini G, Martín R, Benítez J. Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 1997; 7: 85-93.
4. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173-181.
5. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
6. Gervasini G, Martínez C, Agúndez JA, Garcia-Gamito FJ, Benítez J. Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline. Pharmacogenetics 2001; 11: 29-37.
7. Facciola G, Hidestrand M, von Bahr C, Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001; 56: 881-888.
8. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 22: 25-28.
9. Daikh BE, Lasker JM, Raucy JL, Koop DR. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 1994; 271: 1427-1433.
10. Rifkind AB, Lee C, Chang TK, Waxman DJ. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995; 320: 380-389.
11. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
12. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996; 31: 157-161.
13. Dorado P, Berecz R, Norberto MJ, Yasar Ü, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Phamacol 2003; 59: 221-225.
14. Llerena A, Dorado P, Berecz R, Gonzalez AP, Peñas-Iledo EM. Effects of CYPZD6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2003; submitted.
15. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
16. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109.